Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
Appointed director
Cascadian Therapeutics, Inc. (CASC) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/09/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Agreement and Plan of Merger, by and among Seattle Genetics, Inc., Valley Acquisition Sub, Inc. and Cascadian Therapeutics, Inc. (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Cascadian Therapeutics, Inc. on January 31, 2018)"
02/07/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 1, 2018 CASCADIAN THERAPEUTICS, INC. Delaware 001-33882 26-0868560 3101 Western Avenue, Suite 600 Seattle, Washington 98121 801-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 u...",
"Amendment to Scott Myers Confidentiality Agreement",
"Form of Amendment to Employee Confidentiality, Invention Assignment and Non-Compete Agreements",
"Amendment to Scott Myers Employment Agreement",
"Form of Amendment to Executive Employment Agreements",
"Form of Transaction Bonus Agreement"
01/31/2018 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 30, 2018 CASCADIAN THERAPEUTICS, INC. Delaware 001-33882 26-0868560 3101 Western Avenue, Suite 600 Seattle, Washington 98121 801-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 u...",
"Agreement and Plan of Merger, by and among the Company, Seattle Genetics, Inc. and Valley Acquisition Sub, Inc",
"Amendment to the Bylaws of Cascadian Therapeutics, Inc",
"Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline"
11/08/2017 8-K Quarterly results
Docs: "Cascadian Therapeutics Reports Third Quarter 2017 Financial Results"
08/08/2017 8-K Quarterly results
06/09/2017 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cascadian Therapeutics, Inc",
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cascadian Therapeutics, Inc"
05/09/2017 8-K Form 8-K - Current report
03/13/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
02/03/2017 8-K Form 8-K - Current report
01/27/2017 8-K Form 8-K - Current report
01/24/2017 8-K Form 8-K - Current report
01/23/2017 8-K Form 8-K - Current report
12/07/2016 8-K Form 8-K - Current report
11/23/2016 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
10/04/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Cascadian Therapeutics Announces Proposal for Reverse Stock Split"
08/08/2016 8-K Quarterly results
Docs: "Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update"
06/29/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer"
06/28/2016 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock",
"Specimen Series D Convertible Preferred Stock Certificate",
"Cascadian Therapeutics Announces Exercise of Underwriters' Over- Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock"
06/14/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Cascadian Therapeutics Reports Topline ONT-380 “Triplet” Data and Outlines Key Development Strategies"
06/09/2016 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Oncothyreon Inc",
"Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics"
06/02/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Sales Agreement, between Oncothyreon Inc. and Cowen and Company, LLC",
"Opinion of Fenwick & West LLP"
05/19/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Executive Employment Agreement"
05/09/2016 8-K Quarterly results
Docs: "Oncothyreon Reports First Quarter 2016 Financial Results & Provides Corporate Update"
04/01/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement by and between Oncothyreon Inc. and Dr. Diana Hausman",
"Release by and between Oncothyreon Inc. and Dr. Diana Hausman"
03/29/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Offer Letter of Employment by and between Oncothyreon Inc. and Scott Myers",
"Form of Inducement Stock Option Grant",
"Oncothyreon Appoints Scott D. Myers Chief Executive Officer"
11/12/2013 8-K Quarterly results
Docs: "Oncothyreon Reports Third Quarter 2013 Financial Results Company to Hold Conference Call at 4:30 p.m. EST Today"
11/08/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "Oncothyreon Announces Presentation of Data from Phase 1Trial of ONT-10"
10/11/2013 8-K Resignation/termination of a director
09/06/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors"
08/06/2013 8-K Quarterly results
Docs: "Oncothyreon Reports Second Quarter 2013 Financial Results Company to Hold Conference Call at 4:30 p.m. EDT Today"
05/09/2013 8-K Quarterly results
Docs: "Oncothyreon Reports First Quarter 2013 Financial Results Company to Hold Earnings and Pipeline Update Conference Call at 4:30 p.m. EDT Today"
03/14/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Oncothyreon Reports Full Year and Fourth Quarter 2012 Financial Results Company to Hold Conference Call at 8:30 a.m. EST Today"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy